Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, "Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC," were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21.

21 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

Pre-clinical data on MM-121 and MM-111 to be presented at AACR 2010

Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.

17 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

RTI Biologics launches BTB Select and BioCAP Select implants for use in sports medicine surgeries at AAOS 2010

RTI Biologics Inc., the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching two new biologic implants for use in sports medicine surgeries at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans this week.

11 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Researchers identify potential therapeutic targets for treatment of neuroblastoma

A team of researchers, led by Patrick Mehlen, at Universit- de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma - the most frequent solid tumor in young children- by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

15 Feb 2010

RTI Biologics supports Haiti relief efforts with Matrix HD sterilized dermis allografts donation

RTI Biologics Inc., the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated Matrix HD™ sterilized dermis allografts to use in limb salvage procedures for victims of the recent natural disasters in Haiti.

12 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

Boston researchers identify new mechanism that inhibit tumor growth in mice

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

9 Feb 2010

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

4 Feb 2010

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

29 Jan 2010

Xenograft News and Research

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Researchers use genistein to improve outlook of pancreatic cancer

Pre-clinical data on MM-121 and MM-111 to be presented at AACR 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Tips offered in April 2010 issue of American Journal Of Pathology

RTI Biologics launches BTB Select and BioCAP Select implants for use in sports medicine surgeries at AAOS 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Researchers identify potential therapeutic targets for treatment of neuroblastoma

RTI Biologics supports Haiti relief efforts with Matrix HD sterilized dermis allografts donation

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

Medicinal chemistry paper related to the discovery of CUDC-101 published

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Boston researchers identify new mechanism that inhibit tumor growth in mice

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News